Bio-Rad Laboratories, Inc. saw a decline in its stock price after reporting quarterly results that slightly beat expectations. Analysts have adjusted their forecasts, expecting revenues of US$2.53b in 2025. However, EPS forecasts have decreased.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing